Wang M - Search Results

1

In vivo analysis of a genetically modified adenoviral vector targeted to human CD40 using a novel transient transgenic model.

Izumi M, Kawakami Y, Glasgow JN, Belousova N, Everts M, Kim-Park S, Yamamoto S, Wang M, Le LP, Reynolds PN, Curiel DT. Izumi M, et al. Among authors: wang m. J Gene Med. 2005 Dec;7(12):1517-25. doi: 10.1002/jgm.806. J Gene Med. 2005. PMID: 16170831

2

Targeted tumor killing via an intracellular antibody against erbB-2.

Deshane J, Siegal GP, Alvarez RD, Wang MH, Feng M, Cabrera G, Liu T, Kay M, Curiel DT. Deshane J, et al. Among authors: wang mh. J Clin Invest. 1995 Dec;96(6):2980-9. doi: 10.1172/JCI118370. J Clin Invest. 1995. PMID: 8675670 Free PMC article.

3

A targetable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo.

Reynolds PN, Zinn KR, Gavrilyuk VD, Balyasnikova IV, Rogers BE, Buchsbaum DJ, Wang MH, Miletich DJ, Grizzle WE, Douglas JT, Danilov SM, Curiel DT. Reynolds PN, et al. Among authors: wang mh. Mol Ther. 2000 Dec;2(6):562-78. doi: 10.1006/mthe.2000.0205. Mol Ther. 2000. PMID: 11124057 Free article.

4

Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma.

Mahasreshti PJ, Navarro JG, Kataram M, Wang MH, Carey D, Siegal GP, Barnes MN, Nettelbeck DM, Alvarez RD, Hemminki A, Curiel DT. Mahasreshti PJ, et al. Among authors: wang mh. Clin Cancer Res. 2001 Jul;7(7):2057-66. Clin Cancer Res. 2001. PMID: 11448924

5

Strategies to accomplish targeted expression of transgenes in ovarian cancer for molecular therapeutic applications.

Casado E, Gomez-Navarro J, Yamamoto M, Adachi Y, Coolidge CJ, Arafat WO, Barker SD, Wang MH, Mahasreshti PJ, Hemminki A, Gonzalez-Baron M, Barnes MN, Pustilnik TB, Siegal GP, Alvarez RD, Curiel DT. Casado E, et al. Among authors: wang mh. Clin Cancer Res. 2001 Aug;7(8):2496-504. Clin Cancer Res. 2001. PMID: 11489832

6

Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses.

Kanerva A, Wang M, Bauerschmitz GJ, Lam JT, Desmond RA, Bhoola SM, Barnes MN, Alvarez RD, Siegal GP, Curiel DT, Hemminki A. Kanerva A, et al. Among authors: wang m. Mol Ther. 2002 Jun;5(6):695-704. doi: 10.1006/mthe.2002.0599. Mol Ther. 2002. PMID: 12027553 Free article.

7

Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors.

Haviv YS, Blackwell JL, Kanerva A, Nagi P, Krasnykh V, Dmitriev I, Wang M, Naito S, Lei X, Hemminki A, Carey D, Curiel DT. Haviv YS, et al. Among authors: wang m. Cancer Res. 2002 Aug 1;62(15):4273-81. Cancer Res. 2002. PMID: 12154029

8

Serum and ascites neutralizing antibodies in ovarian cancer patients treated with intraperitoneal adenoviral gene therapy.

Hemminki A, Wang M, Desmond RA, Strong TV, Alvarez RD, Curiel DT. Hemminki A, et al. Among authors: wang m. Hum Gene Ther. 2002 Aug 10;13(12):1505-14. doi: 10.1089/10430340260185139. Hum Gene Ther. 2002. PMID: 12215271 Clinical Trial. No abstract available.

9

Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon.

Wu H, Dmitriev I, Kashentseva E, Seki T, Wang M, Curiel DT. Wu H, et al. Among authors: wang m. J Virol. 2002 Dec;76(24):12775-82. doi: 10.1128/jvi.76.24.12775-12782.2002. J Virol. 2002. PMID: 12438602 Free PMC article.

10

A model system for the design of armed replicating adenoviruses using p53 as a candidate transgene.

Haviv YS, Takayama K, Glasgow JN, Blackwell JL, Wang M, Lei X, Curiel DT. Haviv YS, et al. Among authors: wang m. Mol Cancer Ther. 2002 Mar;1(5):321-8. Mol Cancer Ther. 2002. PMID: 12489848

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

67,000 results

Search Page

Filters